Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
1997-1-13
|
| pubmed:abstractText |
Long-term disease-free survival following conventional cytotoxic therapy is extremely rare in patients with advanced-stage mantle cell lymphoma (MCL). High-dose conditioning therapy consisting of hyperfractionated total body irradiation (TBI, 14.4 Gy) and cyclophosphamide (200 mg/kg) was therefore offered to 13 patients (four females/nine males) with advanced-stage MCL. The patients were relatively young with a median age of 49 years (range 30-60). High-dose cytarabine and mitoxantrone with granulocyte colony-stimulating factor (G-CSF) support were given for second-line therapy and mobilization of peripheral blood stem cells (PBSC). During cytokine-stimulated marrow recovery, a median of two leukaphereses (range 1-4) were performed. Using direct immunofluorescence analysis including two-color staining, the proportion of CD19+ B cells and CD34+/CD19+ B lymphoid progenitor cells was found to be extremely low with quantities below detection limit in approximately 50% of the autografts. At the time of autografting, nine patients (pts) were in first partial (five pts) or complete (four pts) remission, while four patients had achieved a second complete remission. Following myeloablative therapy a median number of 7.5 x 10(6) CD34+ cells/kg were autografted. The median time for neutrophil (> or = 0.5 x 10(9)/l) and platelet recovery (> or = 20 x 10(9)/l) was 13 and 10 days, respectively. Hematological recovery was delayed in a patient who received 5.8 x 10(6) positively selected CD34+ cells/kg. There was one toxic death 17 days post-transplantation because of overwhelming interstitial pneumonia. Two patients with a history of previous treatment failure relapsed 10 and 11 months post-transplantation, respectively, at sites of previous disease. Ten patients are disease-free with a median follow-up time of 18 months (range 10-47). The results presented here suggest that PBSC-supported high-dose therapy including TBI may provide long-term disease-free survival for patients with advanced-stage mantle cell lymphoma.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0887-6924
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1975-9
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8946940-Adult,
pubmed-meshheading:8946940-Antigens, CD34,
pubmed-meshheading:8946940-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8946940-B-Lymphocytes,
pubmed-meshheading:8946940-Combined Modality Therapy,
pubmed-meshheading:8946940-Cytarabine,
pubmed-meshheading:8946940-Dose-Response Relationship, Drug,
pubmed-meshheading:8946940-Feasibility Studies,
pubmed-meshheading:8946940-Female,
pubmed-meshheading:8946940-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:8946940-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:8946940-Humans,
pubmed-meshheading:8946940-Lymphoma, Non-Hodgkin,
pubmed-meshheading:8946940-Male,
pubmed-meshheading:8946940-Middle Aged,
pubmed-meshheading:8946940-Mitoxantrone,
pubmed-meshheading:8946940-Transplantation Conditioning,
pubmed-meshheading:8946940-Whole-Body Irradiation
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma.
|
| pubmed:affiliation |
Department of Internal Medicine V, University of Heidelberg, Germany.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|